Form 4: Atossa Therapeutics Director Acquires Stock Options

Richard I. Steinhart, a director of Atossa Therapeutics, acquired stock options for 125,000 shares on June 27, 2024.

Summary

• Richard I. Steinhart, a director at Atossa Therapeutics, acquired stock options on June 27, 2024.
• The options are for 125,000 shares of common stock.
• The exercise price is $1.05 per share, reflecting the closing stock price on June 26, 2024.
• The options vest quarterly over 12 months, contingent on continued service.
• The options expire on June 27, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects a director's increased stake in the company, suggesting confidence, but it's a routine filing.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a standard Form 4 filing, which is common for publicly traded companies when insiders (directors, officers, or those holding 10% or more of the company's shares) engage in transactions involving the company's securities. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, used to align the interests of management with those of shareholders.
• The vesting schedule of 12 months is fairly standard.
• The exercise price being set at the closing price on the day prior to the grant is also a typical practice.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that a director has increased confidence in the company's future prospects.

Key Dates